Vertex Pharmaceuticals Inc VX1
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
-
Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
-
Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
-
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 — Data Talk
-
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
-
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
-
Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
-
Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
Trading Information
- Previous Close Price
- €449.75
- Day Range
- €446.55–446.55
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 253.46M
- Market Cap
- $113.18B
- Volume/Avg
- — / 61
Key Statistics
- Price/Earnings (Normalized)
- 27.37
- Price/Sales
- 10.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.73%
Company Profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 6,400
- Website
- https://www.vrtx.com
Competitors
Valuation
|
Metric
|
VX1
|
GMAB
|
ALNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.37 | 22.95 | 29.05 |
Price/Book Value | 6.38 | 3.85 | 22.98 |
Price/Sales | 10.60 | 5.76 | 6.72 |
Price/Cash Flow | 26.90 | 23.42 | 21.67 |
Price/Earnings
VX1
GMAB
ALNY
Financial Strength
|
Metric
|
VX1
|
GMAB
|
ALNY
|
|---|---|---|---|
Quick Ratio | 2.54 | 2.44 | 2.79 |
Current Ratio | 3.19 | 2.46 | 3.05 |
Interest Coverage | — | 3.88 | 3.12 |
Quick Ratio
VX1
GMAB
ALNY
Profitability
|
Metric
|
VX1
|
GMAB
|
ALNY
|
|---|---|---|---|
Return on Assets (Normalized) | 18.99% | 11.74% | 22.09% |
Return on Equity (Normalized) | 26.29% | 21.07% | 149.53% |
Return on Invested Capital (Normalized) | 21.93% | 14.75% | 63.06% |
Return on Assets
VX1
GMAB
ALNY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SL!&BWD | LOCK|yx<G# | $129B | |||
| Moderna Inc
MRNA
| LOCK|!@DJ!T& | LOCK|k< | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|L!blSW% | LOCK|Br$B% | $77B | |||
| argenx SE ADR
ARGX
| LOCK|XbVmb> | LOCK|h! | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%<#T@b# | LOCK|^z | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!@vLT# | LOCK|fQwff | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|q>c<$@<D | LOCK|?h%p | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!@SG^zB | LOCK|&G | $24B | |||
| Incyte Corp
INCY
| LOCK|&LWBh>p | LOCK|&p& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|VK<!N?D | LOCK|!Z | $14B |
United States